HC-based NGS impacts treatment decisions in lung cancer patients with adenocarcinoma

November 16, 2016

DENVER - The use of hybrid capture-based (HC-based) next-generation sequencing (NGS) to identify targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.

Lung cancer is the most common type of cancer with the highest cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for roughly 85% with about 40% being adenocarcinoma. Targeted therapy that targets driver genomic alterations (GAs) significantly prolongs survival in lung adenocarcinoma patients, and tumor genotyping allows for the detection of GAs in approximately 60% of patients. Currently, the technologies (polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization) used for the detection of GAs cannon identify all alterations in EGFR exons and introns or all variants of ALK rearrangements. HC-based NGS is a technology that offers broad gene sequencing, extensive genetic information regarding GAs and exon/intron mutations, gene rearrangements and amplifications. However, the utility of HC-based NGS in clinical practice is yet to be extensively reviewed.

A group of Israeli researchers, led by Dr. Nir Peled, conducted a retrospective study on a cohort of 101 patients with advanced lung cancer that were treated at the Davidoff Cancer Center, Rabin Medical Center, Israel between 11/2011 and 10/2015, who underwent HC-based NGS using broad gene panels. Demographic and clinic-pathologic characteristics, treatments, and outcome data were collected.

The results of the study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), show that of the 101 patients with advanced lung cancer included in the study, the median age at diagnosis was 63 years, 94% of the patients were diagnosed at stage III-IV, 53% were women, 45% were never smokers, and 85% had adenocarcinoma. HC-based NGS was performed before standard EGFR/ALK testing (15% of patients due to lack of tissue) or after testing revealed negative or inconclusive (85% of patients) results. HC-based NGS was performed before treatment with 1st-line therapy in 51.5% patients and after treatment failure in 48.5% of patients. HC-NGS identified clinically actionable GAs in 50% of patients (EGFR 18%, RET 9%, ALK 8%, MET 6%, and ERBB2 5%) and identified EGFR/ALK aberrations not detected via standard screening in 15 patients. HC-based NGS results caused deviations to treatment strategy in 43 patients (42.6%). The overall response rate to targeted therapies in these patients was 65% (complete, 14.7%; partial 50%). Median survival was not reached. Immunotherapy was administered in 33 patients, mostly without an actionable driver, presenting disease control rate of 32% and an association to tumor mutation burden.

The authors comment that, "This study draws attention to the rate of high false negative results in clinical routine practice and may not allow patients to have access to therapy targeting driver mutations. It also can expose patients to immunotherapy as 2nd-line treatment that may not work in this population of patients. Our study is restricted by its retrospective nature, its relatively small sample size, and by being a single-center study. In addition, the high percentage of never smokers, female preponderance, and the relatively young median age of our patient group represent a selection bias with a high pre-test probability for the existence of driver mutation. The results of large future prospective trials such as the National Lung Matrix Trial (NLMT) in the UK, and the Molecular Analysis for Therapy Choice (MATCH) Program, led by the US National Cancer Institute, are thus eagerly anticipated. Nevertheless, the high impact of HC-based NGS on treatment strategy, and the high overall response rate observed in this study, highlight the need for identifying molecular drivers and support the implementation of HC-based NGS in lung cancer."
-end-
Co-authors Anna Belilovski Rozenblum and Nir Peled are members of IASLC.

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,000 lung cancer specialists in over 100 countries. Visit http://www.iaslc.org for more information.

Written by: Jacinta Wiens, PhD, 720-598-1941; jacinta.wiens@iaslc.org

Media Contact: Becky Bunn, 720-254-9509; Becky.Bunn@iaslc.org

International Association for the Study of Lung Cancer

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.